Comprehensive Information & Analysis Report on Antithrombin Market - 2021 to 2028
The global antithrombin market is predicted to reach at a high CAGR during the forecast period (2021-2028).
(EMAILWIRE.COM, September 23, 2021 )
Market Overview
Antithrombin is a protein present in blood that inhibits blood clotting by inactivating thrombin. Antithrombin is produced by the liver and consists of 432 amino acids. There are two major reasons for antithrombin deficiency, which include acquired antithrombin deficiency caused due to other diseases. . If a person is suffering from antithrombin deficiency, her blood will have a tendency to clot too much in the veins, a rare condition called thrombosis.
View full report: https://bit.ly/3CyebTu
Market Dynamics
The global antithrombin market growth is driven by the acceptance of antithrombin in several medical conditions over conventional once is contribute to driving the demand for products which drive the global antithrombin market.
The growing incidence of disease is expected to drive the market growth in the forecast period
The growing incidence of conditions (like sepsis, congenital antithrombin deficiency, disseminated intravascular coagulation (DIC), extracorporeal membrane oxygenation (ECMO)), are likely to increase the growth of the global antithrombin market. Thrombotic diseases require a long term treatment of antithrombin drugs, this contributes to the increase in production and sales of Antithrombin. The increased usage of rapid diagnostic tests, which in turn use antithrombin, drive the demand of the protein in the diagnostic field. Moreover, key players are investing in research and development in order to develop new therapeutics to address the unmet needs. This in turn to drive the growth of the global antithrombin market. For instance, China Biologic Products Holdings, Inc. integrated plasma-based biopharmaceutical company in China develop Human Antithrombin III for treatment of hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures and thromboembolism is in clinical trial phase III. These factors are driving the growth of the market in the forecast period.
Increasing Number of Surgical Procedures, expected to drive the market growth
The global antithrombin market is poised to experience steady growth as excessive bleeding during surgical procedures has increased in occurrence. Antithrombin deficiency can lead to thromboembolism, a condition in which a clot develops in a blood vessel, breaks loose from it, and is carried by the bloodstream to another vessel. This can severely affect the functioning of other organs like kidneys, brain, gastrointestinal tract, and lungs. This can create complications during and after surgeries. The market potential of antithrombins is anticipated to significantly rise on the basis of these factors. Furthermore, the global antithrombin market is expected to gain considerable momentum during the forecast period on account of growing instances of hereditary antithrombin deficiency.
Side effects such as sores, blisters or ulcers in mouth is likely to hinder the market growth
On the contrary, the increased use of biologics and the high cost of antithrombin are the two factors constraining the growth of the market.
Segment Analysis
By Usage
• Therapeutics
• Diagnostics
• Research
• Other
By Type
• Anticoagulant
• Antiplatelet
• Thrombolytic Drug
By Route of Administration
• Oral
• Parenteral
By Source
• Human
• Recombinant Goat milk
• Others
Download free sample: https://bit.ly/3kzr0a9
Geographical Analysis
Asia-pacific region holds the largest market share global antithrombin market
The Asia-pacific region is expected to show a high growth due to the developing nations such as India and China that are embracing new treatment procedures and techniques to combat various diseases. The increase in non-refundable incomes developing countries and their increasing capability to invest more money for advanced healthcare creates more opportunities for the market in the Asia Pacific. Although the occurrence of venous thromboembolism (VTE) in Asian populations is lesser than in Western countries, the total burden of VTE in Asia has been substantially underestimated. Factors that may explain the lower prevalence of VTE in Asian populations relative to Western populations comprise the incomplete availability of epidemiological data in Asia, ethnic differences in the genetic predilection to VTE, underdiagnoses, low awareness toward thrombotic disease, and possibly less symptomatic VTE in Asian patients. In recent years the awareness of the disease is increasing, raising the need for diagnosis and treatment.
Competitive Landscape
The antithrombin market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, and Lee Biosolutions Inc., BDI Pharma among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antithrombin market globally.
Related Topic's
Bovine Mastitis Market, Adenosine Triphosphate Test Kit Market, Gonadotropin-Releasing Hormone Agonists and Antagonists Drugs Market, USA Opioids Drug Market, Gastroretentive Drug Delivery System Market
Market Overview
Antithrombin is a protein present in blood that inhibits blood clotting by inactivating thrombin. Antithrombin is produced by the liver and consists of 432 amino acids. There are two major reasons for antithrombin deficiency, which include acquired antithrombin deficiency caused due to other diseases. . If a person is suffering from antithrombin deficiency, her blood will have a tendency to clot too much in the veins, a rare condition called thrombosis.
View full report: https://bit.ly/3CyebTu
Market Dynamics
The global antithrombin market growth is driven by the acceptance of antithrombin in several medical conditions over conventional once is contribute to driving the demand for products which drive the global antithrombin market.
The growing incidence of disease is expected to drive the market growth in the forecast period
The growing incidence of conditions (like sepsis, congenital antithrombin deficiency, disseminated intravascular coagulation (DIC), extracorporeal membrane oxygenation (ECMO)), are likely to increase the growth of the global antithrombin market. Thrombotic diseases require a long term treatment of antithrombin drugs, this contributes to the increase in production and sales of Antithrombin. The increased usage of rapid diagnostic tests, which in turn use antithrombin, drive the demand of the protein in the diagnostic field. Moreover, key players are investing in research and development in order to develop new therapeutics to address the unmet needs. This in turn to drive the growth of the global antithrombin market. For instance, China Biologic Products Holdings, Inc. integrated plasma-based biopharmaceutical company in China develop Human Antithrombin III for treatment of hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures and thromboembolism is in clinical trial phase III. These factors are driving the growth of the market in the forecast period.
Increasing Number of Surgical Procedures, expected to drive the market growth
The global antithrombin market is poised to experience steady growth as excessive bleeding during surgical procedures has increased in occurrence. Antithrombin deficiency can lead to thromboembolism, a condition in which a clot develops in a blood vessel, breaks loose from it, and is carried by the bloodstream to another vessel. This can severely affect the functioning of other organs like kidneys, brain, gastrointestinal tract, and lungs. This can create complications during and after surgeries. The market potential of antithrombins is anticipated to significantly rise on the basis of these factors. Furthermore, the global antithrombin market is expected to gain considerable momentum during the forecast period on account of growing instances of hereditary antithrombin deficiency.
Side effects such as sores, blisters or ulcers in mouth is likely to hinder the market growth
On the contrary, the increased use of biologics and the high cost of antithrombin are the two factors constraining the growth of the market.
Segment Analysis
By Usage
• Therapeutics
• Diagnostics
• Research
• Other
By Type
• Anticoagulant
• Antiplatelet
• Thrombolytic Drug
By Route of Administration
• Oral
• Parenteral
By Source
• Human
• Recombinant Goat milk
• Others
Download free sample: https://bit.ly/3kzr0a9
Geographical Analysis
Asia-pacific region holds the largest market share global antithrombin market
The Asia-pacific region is expected to show a high growth due to the developing nations such as India and China that are embracing new treatment procedures and techniques to combat various diseases. The increase in non-refundable incomes developing countries and their increasing capability to invest more money for advanced healthcare creates more opportunities for the market in the Asia Pacific. Although the occurrence of venous thromboembolism (VTE) in Asian populations is lesser than in Western countries, the total burden of VTE in Asia has been substantially underestimated. Factors that may explain the lower prevalence of VTE in Asian populations relative to Western populations comprise the incomplete availability of epidemiological data in Asia, ethnic differences in the genetic predilection to VTE, underdiagnoses, low awareness toward thrombotic disease, and possibly less symptomatic VTE in Asian patients. In recent years the awareness of the disease is increasing, raising the need for diagnosis and treatment.
Competitive Landscape
The antithrombin market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, and Lee Biosolutions Inc., BDI Pharma among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antithrombin market globally.
Related Topic's
Bovine Mastitis Market, Adenosine Triphosphate Test Kit Market, Gonadotropin-Releasing Hormone Agonists and Antagonists Drugs Market, USA Opioids Drug Market, Gastroretentive Drug Delivery System Market
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results